MedTrace Logo

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

NCT05054218 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 336

Last updated 2023-04-14

No results posted yet for this study

Summary

Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose

Conditions

  • Covid19
  • SARS-CoV2 Infection

Interventions

BIOLOGICAL

mRNA-1273

Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.

Sponsors & Collaborators

  • ModernaTX, Inc.

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Anna Giuliano, PhD · Moffitt Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2022-07-16
Completion
2022-08-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05054218 on ClinicalTrials.gov